在激素受体阳性/人表皮生长因子受体2阴性（HR+/HER2-）转移性乳腺癌中，在先使用的CDK4/6抑制剂治疗进展后继续使用CDK4/6抑制剂是否有作用？ - Suppr

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

作者信息

Giordano A, Lin N U, Tolaney S M, Mayer E L

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.

出版信息

Ann Oncol. 2024 Jan;35(1):10-14. doi: 10.1016/j.annonc.2023.11.003. Epub 2023 Nov 11.

DOI:10.1016/j.annonc.2023.11.003

PMID:37952893

Abstract

摘要

相似文献

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Ann Oncol. 2024 Jan;35(1):10-14. doi: 10.1016/j.annonc.2023.11.003. Epub 2023 Nov 11.

Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.

Breast Cancer Res Treat. 2020 Feb;180(1):21-32. doi: 10.1007/s10549-020-05528-2. Epub 2020 Jan 22.

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.

Breast Cancer. 2021 Jan;28(1):206-215. doi: 10.1007/s12282-020-01150-8. Epub 2020 Aug 28.

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.

Oncologist. 2022 Jun 8;27(6):441-446. doi: 10.1093/oncolo/oyac075.

Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR/HER2 Breast Cancer.

Clin Breast Cancer. 2020 Feb;20(1):1-11. doi: 10.1016/j.clbc.2019.06.017. Epub 2019 Aug 23.

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).

Breast Cancer. 2023 Nov;30(6):943-951. doi: 10.1007/s12282-023-01485-y. Epub 2023 Jul 24.

Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.

Target Oncol. 2023 May;18(3):327-358. doi: 10.1007/s11523-023-00957-7. Epub 2023 Apr 19.

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.

Breast. 2020 Dec;54:88-95. doi: 10.1016/j.breast.2020.08.011. Epub 2020 Aug 29.

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.

ESMO Open. 2021 Dec;6(6):100332. doi: 10.1016/j.esmoop.2021.100332. Epub 2021 Dec 1.

Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?

Curr Oncol Rep. 2020 May 16;22(6):57. doi: 10.1007/s11912-020-00917-8.

引用本文的文献

Engineered celastrol liposomes with glycyrrhizic acid augment synergistic antitumor efficacy in breast cancer.

Front Oncol. 2025 May 20;15:1602585. doi: 10.3389/fonc.2025.1602585. eCollection 2025.

CDK4/6 as a Therapeutic Target in HR+/HER2- Breast Cancer Cells-Current Treatment Status.

Cancers (Basel). 2025 Mar 20;17(6):1039. doi: 10.3390/cancers17061039.

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

JAMA Netw Open. 2025 Feb 3;8(2):e2461067. doi: 10.1001/jamanetworkopen.2024.61067.

Continuation of CDK4/6 Inhibition and Switching of Hormonal Therapy After Progression on Prior CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.

Cureus. 2024 Nov 15;16(11):e73738. doi: 10.7759/cureus.73738. eCollection 2024 Nov.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

作者信息

Giordano A, Lin N U, Tolaney S M, Mayer E L

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.

出版信息

Ann Oncol. 2024 Jan;35(1):10-14. doi: 10.1016/j.annonc.2023.11.003. Epub 2023 Nov 11.

DOI:10.1016/j.annonc.2023.11.003

PMID:37952893

Abstract

摘要

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

作者信息

机构信息

出版信息

相似文献

引用本文的文献